- Home
- NN vs RXRX Comparison
NN vs RXRX Comparison
Compare NN & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$14.82
HOLD
Current Price
$3.37
Company Overview
Basic Information| Metric | NN | RXRX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | 96 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NN | RXRX |
|---|---|---|
| Price | $14.82 | $3.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 1.5M | ★ 11.3M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $74,681,000.00 |
| Revenue This Year | N/A | $12.11 |
| Revenue Next Year | N/A | $82.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.92 |
| 52 Week Low | $10.84 | $2.80 |
| 52 Week High | $19.91 | $7.18 |
Technical Indicators
Market Signals| Indicator | NN | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 52.54 |
| Support Level | $13.66 | $2.89 |
| Resistance Level | $15.82 | $5.03 |
| Average True Range (ATR) | 1.34 | 0.17 |
| MACD | -0.37 | 0.04 |
| Stochastic Oscillator | 7.37 | 87.02 |
Price Performance
Historical Comparison NN
RXRX
About NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.